Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥734.8bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥1.39T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥681.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥7.9bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥19.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥13.0bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥801.4bnat 2023-09-30Cons.Assets
Total assets¥715.3bnat 2023-03-31Cons.Assets
Total assets¥740.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥556.2bnat 2023-09-30Cons.Liabilities
Total liabilities¥472.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥245.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥137.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥86.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥133.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥81.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥53.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥9m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥3.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥13.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥134.192023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥112.262023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥196.72022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥121.192023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥180.672022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio30.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥895m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-09-30¥5.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-09-30¥436m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-09-30¥709.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-09-30¥684.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥24.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥678m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥764.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥734.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥29.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥8.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥656.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥632.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥709.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥681.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 581
ItemContextValueUnit
Provision for directors bonuses sgaPrior1YTDDuration21000000JPY
Provision for directors bonuses sgaCurrentYTDDuration21000000JPY
Retirement benefit expenses sgaPrior1YTDDuration143000000JPY
Retirement benefit expenses sgaCurrentYTDDuration146000000JPY
Welfare expenses sgaPrior1YTDDuration3871000000JPY
Welfare expenses sgaCurrentYTDDuration3845000000JPY
Vehicle expenses sgaPrior1YTDDuration562000000JPY
Vehicle expenses sgaCurrentYTDDuration523000000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration-83000000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration14000000JPY
Depreciation sgaPrior1YTDDuration2746000000JPY
Depreciation sgaCurrentYTDDuration2934000000JPY
Amortization of goodwill sgaPrior1YTDDuration149000000JPY
Amortization of goodwill sgaCurrentYTDDuration134000000JPY
Rent expenses sgaPrior1YTDDuration3997000000JPY
Rent expenses sgaCurrentYTDDuration4238000000JPY
Taxes and dues sgaPrior1YTDDuration1039000000JPY
Taxes and dues sgaCurrentYTDDuration1093000000JPY
Exepences before deduction of temporary consumption tax payment sgaPrior1YTDDuration3153000000JPY
Exepences before deduction of temporary consumption tax payment sgaCurrentYTDDuration3326000000JPY
Other sgaPrior1YTDDuration9770000000JPY
Other sgaCurrentYTDDuration10434000000JPY
Selling general and administrative expensesPrior1YTDDuration48823000000JPY
Selling general and administrative expensesCurrentYTDDuration50142000000JPY
Operating incomePrior1YTDDuration5835000000JPY
Operating incomeCurrentYTDDuration6492000000JPY
Interest income noiPrior1YTDDuration29000000JPY
Interest income noiCurrentYTDDuration27000000JPY
Dividends income noiPrior1YTDDuration745000000JPY
Dividends income noiCurrentYTDDuration677000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration71000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration335000000JPY
Real estate rent noiPrior1YTDDuration416000000JPY
Real estate rent noiCurrentYTDDuration418000000JPY
Other noiPrior1YTDDuration552000000JPY
Other noiCurrentYTDDuration302000000JPY
Non operating incomePrior1YTDDuration1815000000JPY
Non operating incomeCurrentYTDDuration1761000000JPY
Interest expenses noePrior1YTDDuration39000000JPY
Interest expenses noeCurrentYTDDuration31000000JPY
Bond issuance cost noePrior1YTDDuration－JPY
Bond issuance cost noeCurrentYTDDuration83000000JPY
Rent expenses on real estates noePrior1YTDDuration111000000JPY
Rent expenses on real estates noeCurrentYTDDuration88000000JPY
Other noePrior1YTDDuration106000000JPY
Other noeCurrentYTDDuration105000000JPY
Non operating expensesPrior1YTDDuration257000000JPY
Non operating expensesCurrentYTDDuration308000000JPY
Ordinary incomePrior1YTDDuration7392000000JPY
Ordinary incomeCurrentYTDDuration7945000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass